natgillin/translations-raw huggingface dataset:
Effekten af Enbrel blev sammenlignet med mehotrexat i et randomiseret, aktivt kontrolleret forsøg med blindet radiografisk evaluering som primært mål hos 632 vosne patienter med aktiv reumatoid artrit (<3 års varighed), som ikke tidligere var blevet behandlet med methotrexat.
The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (<3 years duration) who had never received treatment with methotrexate.
Effekten af Enbrel blev sammenlignet med methotrexat i et randomiseret, aktivt kontrolleret forsøg med blindet radiografisk evaluering som primært mål hos 632 vosne patienter med aktiv reumatoid artrit (<3 års varighed), som ikke tidligere var blevet behandlet med methotrexat.
The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (<3 years duration) who had never received treatment with methotrexate.
Effekten af Enbrel blev vurderet i et randomiseret, dobbeltblindt placebo-kontrolleret studie med 211 pædiatriske patienter i alderen 4 til 17 år med moderat til svær plaque psoriasis (defineret ved en sPGA score  3, omfattende  10 % af BSA og PASI 12).
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12).
Effekten af Enbrel blev vurderet i et randomiseret, dobbeltblindt placebo-kontrolleret studie med 211 pædiatriske patienter i alderen 4 til 17 år med moderat til svær plaque psoriasis (defineret ved en sPGA score  3, omfattende  10 af BSA og PASI 12).
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by a sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12).
Effekten af Enbrel blev vurderet i et randomiseret, dobbeltblindt placebo-kontrolleret studie med 211 pædiatriske patienter i alderen 4 til 17 år med moderat til svær plaque psoriasis (defineret ved en sPGA score  3, omfattende  10 af BSA og PASI 12).
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12).
Effekten af Enbrel blev vurderet i et randomiseret, dobbeltblindt, placebo-kontrolleret studie med 211 pædiatriske patienter i alderen 4 til 17 år med moderat til svær plaque psoriasis (defineret ved en sPGA score  3, omfattende  10 % af BSA og PASI 12).
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12).
Effekten af Enbrel blev vurderet i et randomiseret, dobbeltblindt, placebo-kontrolleret studie med 211 pædiatriske patienter i alderen 4 til 17 år med moderat til svær plaque psoriasis (defineret ved en sPGA score  3, omfattende  10 af BSA og PASI 12).
The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA score ≥ 3, involving ≥ 10% of the BSA, and PASI ≥ 12).
Effekten af Enbrel over for ankyloserende spondylitis blev bedømt i 3 randomiserede, dobbeltblinde studier, hvor indgivelse af 25 mg Enbrel to gange om ugen blev sammenlignet med placebo.
The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies comparing twice-weekly administration of 25 mg Enbrel with placebo.
Effekten af Enviage på warfarins farmakokinetik er ikke blevet evalueret.
The effects of Enviage on warfarin pharmacokinetics have not been evaluated.
Effekten af enzalutamid hos patienter, som tidligere har fået abirateronacetat, er ikke undersøgt.
The efficacy of enzalutamide in patients who have previously received abiraterone acetate has not been studied.
Effekten af Eperzan blev vurderet i et randomiseret (2:1), ublindet, insulin glargin-kontrolleret non- inferioritetsstudie (N = 735) af 3 års varighed.
The efficacy of Eperzan was evaluated in a 3-year, randomised (2:1), open-label, insulin glargine-controlled noninferiority study (n = 735).
Effekten af Eperzan blev vurderet i et randomiseret, ublindet, liraglutid-kontrolleret non-inferioritetsstudie (N = 805) af 32 ugers varighed.
The efficacy of Eperzan was evaluated in a 32-week, randomised, open-label, liraglutide-controlled noninferiority study (N = 805).
Effekten af Exelon depotplastre hos patienter med Alzheimers demens er blevet påvist i et 24-ugers dobbeltblindet, placebo-kontrolleret kernestudie og dets open label-forlængelsesfase og i et 48-ugers dobbelblindet komparator studie.
The efficacy of Exelon transdermal patches in patients with Alzheimer’s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study.
Effekten af filgrastim hos patienter med udtalt nedsættelse af myeloide stamceller er ikke undersøgt.
The effects of filgrastim in patients with substantially reduced myeloid progenitors have not been studied.
Effekten af filgrastim på neutropeni, der er forårsaget af en knoglemarvsinfiltrerende infektion eller malignitet, kendes ikke.
The effects of filgrastim on neutropenia due to bone marrow-infiltrating infection or malignancy have not been well established.
Effekten af fluticasonfuroat næsespray 110 mikrogram 1 gang daglig blev bekræftet i en post hoc-analyse over 6 og 12 uger i det samme kliniske forsøg samt i et 6 ugers HPA-akse- sikkerhedsforsøg.
Post-hoc analysis over 6 and 12 weeks in the same study, as well as 6-week HPA axis safety study, supported the efficacy of fluticasone furoate nasal spray 110 micrograms once daily.
Effekten af fluticasonfuroat næsespray 110 mikrogram 1 gang daglig blev bekræftet i en post hoc-analyse over 6 og 12 uger i det samme kliniske studie samt i et 6 ugers HPA-akse- sikkerhedsstudie.
Post-hoc analysis over 6 and 12 weeks in the same study, as well as 6-week HPA axis safety study, supported the efficacy of fluticasone furoate nasal spray 110 micrograms once daily.
Effekten af FORSTEO hos mænd og kvinder (N=428), der fik langvarig systemisk glukokortikoidbehandling (ækvivalent med 5 mg eller mere prednison i mindst 3 måneder) blev vist i den 18 måneder primære fase i et 36 måneder, randomiseret, dobbeltblindet, comparator-kontrolleret forsøg (alendronat 10 mg/dag).
The efficacy of FORSTEO in men and women (N=428) receiving sustained systemic glucocorticoid therapy (equivalent to 5 mg or greater of prednisone for at least 3 months) was demonstrated in the 18- month primary phase of a 36 month, randomised, double-blind, comparator-controlled study (alendronate 10 mg/day).
Effekten af Gardasil 9 hos kvinder på mellem 16 og 26 år blev vurderet i et aktivt, komparator- kontrolleret, dobbeltblindet, randomiseret klinisk studie (Protokol 001), som inkluderede i alt 14.204 kvinder (Gardasil 9 = 7.099; qHPV-vaccine = 7.105).
The efficacy of Gardasil 9 in 16- through 26-year-old women was assessed in an active comparator-controlled, double-blind, randomized clinical study (Protocol 001) that included a total of 14,204 women (Gardasil 9 = 7,099; qHPV vaccine = 7,105).
Effekten af Gardasil 9 mod cervikal biopsi relateret til HPV-type 6, 11, 16, 18, 31, 33, 45, 52 og 58 sammenlignet med qHPV-vaccine var 95,9% (95% CI 92,7; 97,9) med 11/6016 versus 262/6018 tilfælde.
The efficacy of Gardasil 9 against cervical biopsy related to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 compared to qHPV vaccine was 95.9% (95% CI 92.7 ; 97.9) with 11/6016 versus 262/6018 cases.
Effekten af Gardasil 9 mod CIN 2 og værre relateret til HPV-type 6, 11, 16, 18, 31, 33, 45, 52 og 58 sammenlignet med qHPV-vaccine var 94,4% (95% CI 78,8; 99,0) med 2/5.952 versus 36/5.947 tilfælde.
The efficacy of Gardasil 9 against CIN 2 and worse related to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 compared to qHPV vaccine was 94.4% (95% CI 78.8 ; 99.0) with 2/5,952 versus 36/5,947 cases.
Effekten af Gardasil 9 mod CIN 3 relateret til HPV-type 6, 11, 16, 18, 31, 33, 45, 52 og 58 sammenlignet med qHPV-vaccine var 100% (95% CI 46,3; 100,0) med 0/5.952 versus 8/5.947 tilfælde.
The efficacy of Gardasil 9 against CIN 3 related to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 compared to qHPV vaccine was 100% (95% CI 46.3 ; 100.0) with 0/5,952 versus 8/5,947 cases.
Effekten af gentagne infusioner med infliximab blev undersøgt i et 1-års klinisk studie (ACCENT I).
The efficacy of repeated infusions with infliximab was studied in a 1-year clinical study (ACCENT I).
Effekten af gentagne infusioner med infliximab hos patienter med fistulerende Crohns sygdom blev undersøgt i et 1-års klinisk studie (ACCENT II).
The efficacy of repeated infusions with infliximab in patients with fistulising Crohn’s disease was studied in a 1-year clinical study (ACCENT II).
Effekten af gentagne MabThera-forløb på udviklingen af neutropeni hos patienter med granulomatose med polyangiitis eller mikroskopisk polyangiitis er ikke undersøgt i kliniske studier.
The effect of multiple MabThera courses on the development of neutropenia in granulomatosis with polyangiitis and microscopic polyangiitis patients has not been studied in clinical trials.
Effekten af hormonale kontraceptiva kan være nedsat i op til 28 dage efter administration af EMEND.
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of EMEND.
Effekten af hormonel kontraception kan være nedsat under og i 28 dage efter behandling med fosaprepitant.
The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant.
Effekten af Ilaris i en undergruppe af unge SJIA-patienter i alderen 16 til 20 år var i overensstemmelse med effekten observeret hos patienter under 16 år.
Efficacy of Ilaris in a subset of young adult SJIA patients aged 16 to 20 years was consistent with the efficacy observed for patients less than 16 years of age.
Effekten af infliximab blev vurderet i to multicenter, randomiserede, dobbeltblinde studier: SPIRIT og EXPRESS.
The efficacy of infliximab was assessed in two multicentre, randomised, double-blind studies: SPIRIT and EXPRESS.
Effekten af insulin glargin (en gang dagligt) på diabetisk retinopati blev undersøgt i et 5 års open-label NPH-kontrolleret studie (NPH givet 2 gange dagligt) med 1024 patienter med type 2 diabetes, i hvilket progression af retinopati med 3 eller flere trin på Early Treatment Diabetic Retinopathy Study (ETDRS) standarden, blev undersøgt ved hjælp af fundus-fotografering.
Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography.
Effekten af insulin glargin (en gang dagligt) på diabetisk retinopati blev undersøgt i et 5 års open-label NPH-kontrolleret studie (NPH givet 2 gange dagligt) med 1024 patienter med type 2 diabetes, i hvilket progression af retinopati med 3 eller flere trin på Early Treatment Diabetic Retinopathy Study (ETDRS) standarden, blev undersøgt ved hjælp af fundus-fotografering.
Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5-year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography.
Effekten af insulin glargin 100 enheder/ml (en gang daglig) på diabetisk retinopati blev undersøgt i et 5 års open-label NPH-kontrolleret studie (NPH givet 2 gange daglig) med 1024 patienter med type 2- diabetes, i hvilket progression af retinopati med 3 eller flere trin på Early Treatment Diabetic Retinopathy Study (ETDRS) standarden, blev undersøgt ved hjælp af fundus-fotografering.
Effects of insulin glargine 100 units/ml (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography.
Effekten af Jetrea blev påvist i 2 multicenter, randomiserede, dobbeltmaskerede, placebokontrollerede studier af 6 måneders varighed hos patienter med VMT.
The efficacy of JETREA was demonstrated in 2 multicentre, randomised, double-masked, placebo-controlled, 6-month studies in patients with VMT.
Effekten af kombinationen af irbesartan og hydrochlorthiazid på fertilitet er ikke evalueret i dyrestudier, da der ikke har været tegn på skadelig effekt på fertiliteten hos dyr eller mennesker med de individuelle stoffer.
The effects of the irbesartan and hydrochlorothiazide combination on fertility have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals or humans with either irbesartan or hydrochlorothiazide when administered alone.
Effekten af kombinationsbehandling med irbesartan og hydrochlorthiazid på morbiditet og mortalitet  er ikke undersøgt.
The effect of the combination of irbesartan and hydrochlorothiazide on morbidity and mortality has not been studied.
Effekten af lamivudin er ikke påvist hos patienter som er co-inficerede med hepatitis Delta eller hepatitis C. Der bør udvises forsigtighed ved behandling af disse patienter.
The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established and caution is advised.
Effekten af Leflunomid Winthrop blev vist i et kontrolleret randomiseret dobbeltblindt forsøg 3L01 med 188 patienter med arthritis psoriatica, behandlet med 20mg/dag.
The efficacy of Leflunomide Winthrop was demonstrated in one controlled, randomised, double blind study 3L01 in 188 patients with psoriatic arthritis, treated at 20 mg/day.
Effekten af Leflunomid Winthrop i behandlingen af reumatoid artrit er vist i 4 kontrollerede forsøg (1 i fase II og 3 i fase III).
The efficacy of Leflunomide Winthrop in the treatment of rheumatoid arthritis was demonstrated in 4 controlled trials (1 in phase II and 3 in phase III).
Effekten af levetiracetam som monoterapi behandling blev påvist i et dobbeltblindt, ækvivalensstudie med parallelle grupper med carbamazepin depottabletter (CR) hos 576 patienter over 16 år med ny eller nyligt diagnosticeret epilepsi.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non- inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy.
Effekten af linaclotid er dokumenteret i to randomiserede, dobbeltblinde, placebokontrollerede fase 3 kliniske studier hos patienter med IBS-C.
The efficacy of linaclotide was established in two randomised, double-blind, placebo-controlled Phase 3 clinical studies in patients with IBS-C.
Effekten af Lonsurf på samlet overlevelse var ens hos patienter i alderen <65 år og ≥65 år.
The effect of Lonsurf on overall survival was similar in patients <65 years and ≥65 years of age.
Effekten af medicin såsom ciclosporin, mycophenolatmofetil og tacrolimus (medicin, som anvendes til transplantationspatienter) kan reduceres af Renagel.
The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used in transplant patients) may be reduced by Renagel.
Effekten af medicin såsom ciclosporin, mycophenolatmofetil og tacrolimus (medicin, som anvendes til transplantationspatienter) kan reduceres af Tasermity.
The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used in transplant patients) may be reduced by Tasermity.
Effekten af metafylaktisk brug af Zuprevo blev påvist i en placebo-kontrolleret multicenter- feltundersøgelse, hvor udbrud af klinisk sygdom var bekræftet (dvs. at dyr i mindst 30% af stierne, som delte luftrum, havde kliniske symptomer på SRD, herunder mindst 10% dyr pr. sti inden for 1 dag; eller 20% inden for 2 dage; eller 30% inden for 3 dage).
The efficacy of metaphylactic use of Zuprevo was demonstrated in a placebo controlled multi-centre field study, when outbreak of clinical disease was confirmed (i.e. animals in at least 30% of the pens sharing the same airspace showed clinical signs of SRD, including at least 10% animals per pen within 1 day; or 20% within 2 days or 30% within 3 days).
Effekten af nedsat leverfunktion på bortezomibs farmakokinetik i doseringsintervallet 0,5-1,3 mg/m2 blev undersøgt i et fase I-forsøg i den første behandlingscyklus hos 61 patienter med primært solide tumorer og nedsat leverfunktion i varierende grad.
The effect of hepatic impairment on the pharmacokinetics of bortezomib was assessed in a Phase I study during the first treatment cycle, including 61 patients primarily with solid tumors and varying degrees of hepatic impairment at bortezomib doses ranging from 0.5 to 1.3 mg/m2.
Effekten af og sikkerheden ved Numient på patienter med Parkinsons sygdom på et fremskredent stadie er blevet evalueret i 2 dobbeltblinde, aktiv-kontrollerede forsøg: parallel-forsøg ADVANCE-PD (forsøg IPX066-B09-02; 22 uger) og overkrydsningsforsøg ASCEND-PD (forsøg IPX066-B-09-06 del 1; 11 uger).
The efficacy and safety of Numient in patients with advanced stage Parkinson’s disease have been evaluated in 2 double-blind, active-controlled studies: parallel study ADVANCE-PD (study IPX066-B09-02; 22 weeks) and cross-over study ASCEND-PD (study IPX066-B-09-06 Part 1; 11 weeks).
Effekten af ORENCIA på graviditet kendes ikke, så du må ikke anvende ORENCIA, hvis du er gravid, medmindre lægen specifikt anbefaler det. hvis du er en kvinde i den fødedygtige alder, skal du anvende sikker prævention, mens du anvender ORENCIA og i op til 14 uger efter sidste dosis.
The effects of ORENCIA in pregnancy are not known, so do not use ORENCIA if you are pregnant unless your doctor specifically recommends it. if you are a woman who could become pregnant, you must use reliable contraception (birth control) while using ORENCIA and up to 14 weeks after the last dose.
Effekten af oseltamivir er ikke solidt dokumenteret hos immunkompromitterede patienter, hverken ved behandling eller forebyggelse af influenza (se pkt.
The efficacy of oseltamivir in either treatment or prophylaxis of influenza in immunocompromised patients has not been firmly established (see section 5.1).
Effekten af oseltamivir ved forebyggelse af naturligt forekommende influenza er påvist i en post- eksponeringsundersøgelse med husstande udsat for smitte, der inkluderede voksne, unge og børn i alderen 1 til 12 år, både som indeks tilfælde og som familiekontakter.
The efficacy of oseltamivir in preventing naturally occurring influenza illness has been demonstrated in a post-exposure prevention study in households that included adults, adolescents, and children aged 1 to 12 years, both as index cases and as family contacts.
Effekten af oseltamivir ved forebyggelse af naturligt forekommende influenza er påvist i et post- eksponeringsforebyggelsesstudie med husstande udsat for smitte, der inkluderede voksne, unge og børn i alderen 1 til 12 år, både som indeks tilfælde og som familiekontakter.
The efficacy of oseltamivir in preventing naturally occurring influenza illness has been demonstrated in a post-exposure prevention study in households that included adults, adolescents, and children aged 1 to 12 years, both as index cases and as family contacts.
Effekten af OSSEOR til nedsættelse af risikoen for nye vertebralfrakturer blev bekræftet i TROPOS- studiet, også for osteoporosepatienter uden frakturer på grund af knogleskørhed ved baseline.
Efficacy of OSSEOR to reduce the risk of new vertebral fracture was confirmed in the TROPOS study, including for osteoporotic patients without fragility fracture at baseline.
Effekten af overdosering med filgrastim er ikke dokumenteret.
The effects of filgrastim overdosage have not been established.
Effekten af overdosering på ægdannelse og æglægningsprocessen er ikke blevet fastslået hos kyllinger.
The effects of overdose on egg formation and the egg laying process have not been established in chickens.
Effekten af palonosetron ved forebyggelse af kvalme og opkastning fremkaldt af kemoterapi med kraftig kvalmefremkaldende virkning kan forstærkes ved at supplere med et kortikosteroid indgivet inden kemoterapien.
The efficacy of palonosetron in the prevention of nausea and vomiting induced by highly emetogenic chemotherapy may be enhanced by the addition of a corticosteroid administered prior to chemotherapy.
Effekten af pemetrexed + cisplatin versus gemcitabin + cisplatin som førstevalg til ikke-småcellet lungecancer – ITT population og histologiske undergrupper
Efficacy of pemetrexed + cisplatin vs. gemcitabine + cisplatin in first-line non-small cell lung cancer – ITT population and histology subgroups.
Effekten af pioglitazon (45 mg monoterapi versus placebo) er undersøgt i et mindre 18-ugers klinisk studie af type 2-diabetikere.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics.
Effekten af pneumokok-konjugat-vaccination på nasofaryngeal bærertilstand blev undersøgt i et randomiseret, dobbelt-blindet studie i Israel, i hvilket børn fik enten Prevanar 13 eller Prevenar (7- valent) i 2-, 4-, 6- og 12-måneders alderen.
The effect of pneumococcal conjugate vaccination on nasopharyngeal carriage was studied in a randomised double-blind study in which infants received either Prevenar 13 or Prevenar (7-valent) at 2, 4, 6 and 12 months of age in Israel.
Effekten af produktet på katte med tumorform af FeLV infektion, eller katte samtidig inficeret med FeLV og FIV i terminal fasen, er ikke undersøgt.
Efficacy of the product on cats with a tumorous form of the infection by FeLV, or cats infected by FeLV or coinfected by FIV in terminal stages was not tested.
Effekten af Prometax depotplastre hos patienter med Alzheimers demens er blevet påvist i et 24-ugers dobbeltblindet, placebo-kontrolleret kernestudie og dets open label-forlængelsesfase og i et 48-ugers dobbelblindet komparator studie.
The efficacy of Prometax transdermal patches in patients with Alzheimer’s dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study.
Effekten af Purevax RCP FeLV blev undersøgt i adskillige undersøgelser på laboratoriebetingelser, hvor katte blev vaccineret og inficeret med virulent herpesvirus, calicivirus, parvovirus eller leukæmivirus.
The effectiveness of Purevax RCP FeLV has been studied in several trials in laboratory conditions where cats were vaccinated and infected with virulent herpesvirus, calicivirus, parvovirus or leukaemia virus.
Effekten af Purevax RCPCh FeLV er undersøgt i adskillige undersøgelser på laboratoriebetingelser, hvor katte blev vaccineret og inficeret med virulent herpesvirus, calicivirus, C. felis, parvovirus eller leukæmivirus.
The effectiveness of Purevax RCPCh FeLV has been studied in several trials in laboratory conditions where cats were vaccinated and infected with virulent herpesvirus, calicivirus, C. felis, parvovirus or leukaemia virus.
Effekten af qHPV-vaccine hos kvinder på mellem 24 og 45 år blev vurderet i et placebo-kontrolleret, dobbeltblindet, randomiseret klinisk fase III studie (Protokol 019, FUTURE III) og inkluderede i alt 3.817 kvinder.
The efficacy of qHPV vaccine in 24- through 45-year-old women was assessed in 1 placebo- controlled, double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women.